MedTrace Logo

Recurrence of Hereditary Hemorrhagic Telangiectasia (HHT) After Liver Transplantation

NCT03942315 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2019-05-08

No results posted yet for this study

Summary

Liver transplantation (LT) has been proposed as a curative treatment in hereditary hemorrhagic telangiectasia (HHT) with severe hepatic involvement. The investigating team provides a long-term evaluation of graft status after LT for HHT with a focus on the risk of recurrence. The present study included all patients prospectively followed up after LT for HHT in the Lyon Liver Transplant Unit from 1993 to 2010 with a survival of more than 1 year.

Conditions

  • Hereditary Haemorrhagic Telangiectasia
  • Liver Transplant

Interventions

OTHER

Data collection from standard follow-up after liver transplant

All patients underwent regular follow-up every 6 to 12 months after the first year post-liver transplant (LT). Complete laboratory investigations were performed at each visit. Doppler ultrasonography was performed every 1 to 3 years after LT. Computed tomography (CT) scan and/ or magnetic resonance imaging (MRI) was performed at 1, 5, 10, 15, and 20 years after LT, or when clinically indicated. All available radiological material was reviewed. Cardiac evaluation was performed regularly in patients who received transplant for cardiac failure.

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Jérôme DUMORTIER, MD · Hospices Civils de Lyon (Hôpital Edouard Herriot )

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-01
Primary Completion
2018-02-01
Completion
2018-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03942315 on ClinicalTrials.gov